by James Riley | Nov 21, 2017 | Posters
As CNS Summit came to an end, we left inspired to continue the conversation on emerging industry trends, disruptive technology, and global regulations. From addressing the future of digital biomarkers and wearables to the regulatory implications of international data... by James Riley | Nov 13, 2017 | Blog
As the clinical trial and life science industries evolve, methodologies around trial design, outcome selection, and quality assurance must advance with the industries. To achieve profitability and growth, sponsors must disrupt the status-quo and begin each trial with... by James Riley | Oct 30, 2017 | Press Releases
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 — NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology... by James Riley | Jul 27, 2017 | Publications and Articles
Individuals at clinical high risk (CHR) often present with a mixture of dif culties in addition to subthreshold psychotic symptoms, such as neurocognitive decline, premorbid dysfunction, and anxious/mood disorders.1–4 Heterogeneity impedes research by obscuring...